Heart failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.
DelveInsight’s, “Heart failure Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Know more about Heart failure Report, click here: Heart failure Pipeline Insight
Some of the Heart failure companies working in the market are:
- Eli Lilly and Company
- Bayer
- BioCardia
- Mesoblast Inc.
- Janssen Research & Development
- Pfizer
- Bristol-Myers Squibb
- Actelion Pharmaceuticals
- Tasly Pharmaceuticals
- Ionis Pharmaceuticals
- Innolife
- Imara Inc
- Bristol-Myers Squibb
- Stealth BioTherapeutics
- Bristol Myers Squibb
- Berlin Cures
- Bayer
- AstraZeneca
- Regeneron Pharmaceuticals
- GlaxoSmithKline
- SQ Innovation
- Recardio
- BIAL
- AstraZeneca
- Bristol Myers Squibb
- Imbria Pharmaceuticals
- Tenaya Therapeutics
- RibomicAnd Many Others
DelveInsight’s Heart failure report covers around 100+ products under different phases of clinical development like:
- Late-stage Heart failure products (Phase III)
- Mid-stage Heart failure products (Phase II and Phase I/II)
- Early-stage Heart failure products (Phase I/II and Phase I) along with the details of
- Heart failure Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request for Heart failure Pipeline sample report to know in detail about the Heart failure product segmentation: Phases of Heart failure Drugs
Some of Heart failure Therapies:
- Finerenone (BAY94-8862)
- Omecamtiv Mecarbil
- ACRX-100
- GSK2798745
- LMI 1195-101
- Elamipretide
- FA relaxin
- BMS-986231
- Rexlemestrocel-L
- CardiAMP Cell Therapy
- And Many Others
Click here to know more about the Heart failure therapeutic assessment @ Heart failure treatment drugs and therapies
Current Heart failure Treatment Scenario and Heart failure Emerging Therapies:
- How many companies are developing Heart failure drugs?
- How many Heart failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart failure and their status?
- What are the key designations that have been granted to the emerging drugs?
Click here to know more about the recent developments in the heart failure domain @ Advancements in Heart failure Clinical trials
Table of Contents:
Introduction
Executive Summary
Heart Failure: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Treatment
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Heart Failure – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AZD-8601: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AZD-3427: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
RBM-003: Ribomic
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Heart Failure Key Companies
Heart Failure Key Products
Heart Failure – Unmet Needs
Heart Failure – Market Drivers and Barriers
Heart Failure – Future Perspectives and Conclusion
Heart Failure Analyst Views
Heart Failure Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/heart-failure-pipeline-insight